Dual CDK4/6-PI3K/mTOR inhibition reinforces cytostatic programs and tumor control in preclinical models of primary and metastatic osteosarcoma.

Although the reduction in metastatic burden with combination therapy did not reach statistical significance relative to palbociclib alone, all three independent measures—qPCR, H&E quantification, and HLA staining—showed concordant decreases in the combination group, suggesting a modest but consistent trend toward further suppression.

also in 111,027 other papers